LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Strona główna・Stock List・United Therapeutics Corp

United Therapeutics Corp

Closed

SectorHealthcare

567.74 0.28

Buy Sell

Overview

Share price change

24h

Current

Min

558

Max

569.94

Key metrics
By Trading Economics
Income	-89M 275M
Sales	-8.7M 782M
P/E Sector Avg	21 49.701
EPS	5.82
Profit margin	35.176
Employees	1,400
EBITDA	-176M 348M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+16.48% upside

Dividends
By Dow Jones
Next Earnings	29 lip 2026

Market Stats
By TradingEconomics
Market Cap	-598M 24B
Previous open	567.46
Previous close	567.74

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

292.345 / 309.245 Support & Resistance

United Therapeutics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 maj 2026, 16:33 UTC

Earnings

Major Market Movers

Webull Shares Slide on 1Q Loss, Soaring Costs

22 maj 2026, 21:10 UTC

Earnings

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 maj 2026, 19:47 UTC

Earnings

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 maj 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 maj 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 maj 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 maj 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 maj 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 maj 2026, 18:35 UTC

Acquisitions, Mergers, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 maj 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 maj 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 maj 2026, 17:54 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

22 maj 2026, 17:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 maj 2026, 17:54 UTC

Market Talk

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 maj 2026, 17:03 UTC

Market Talk

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 maj 2026, 16:54 UTC

Market Talk

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 maj 2026, 16:16 UTC

Market Talk

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 maj 2026, 15:55 UTC

Market Talk

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 maj 2026, 15:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 maj 2026, 15:42 UTC

Market Talk

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 maj 2026, 15:35 UTC

Market Talk

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

16.48% upside

12 Months Forecast

Average 656.85 USD 16.48%

High 738 USD

Low 516 USD

Based on 14 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to United Therapeutics Corp - Dist in the past 3 months.

Technical Score

By Trading Central

292.345 / 309.245Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.